| Name | Title | Contact Details |
|---|
Central States Health and Life Co. of Omaha is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Renue Physical Therapy was established in the Fall of 2011 with one clinic on Bay Road in Saginaw. Our goal from the start was to create a fully patient-focused practice model. We take pride in offering one-on-one treatment with the same therapy team throughout the course of therapy, providing a customized plan that is specific to your needs to help you achieve the best possible outcomes. Since our start in 2011, Renue has grown to more than 12 clinics serving the Great Lakes Bay Region and beyond, with locations in Auburn, Au Gres, Bay City, Bridgeport, Caro, Freeland, Midland, Saginaw and Shields.
Princeton HealthCare System, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Princeton HealthCare System, Inc. is based in Plainsboro, NJ. You can find more information on Princeton HealthCare System, Inc. at www.princetonhcs.org
Women In Need is a Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.